HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NEOG
Neogen Corporation
NEOG lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NEOG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
NEOG's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NEOG PE Valuation
NEOG has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NEOG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
NEOG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over NEOG on earnings, with more consistent year-over-year improvement.
NEOG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.26 | +$4.54 |
| Q2 2026 | -$0.04 | +$4.99 |
| Q1 2026 | -$2.80 | -$0.57 |
| Q4 2025 | -$2.77 | -$0.58 |
| Q3 2025 | -$4.80 | -$4.69 |
| Q2 2025 | -$5.03 | -$4.99 |
| Q1 2025 | -$2.23 | -22400% |
| Q4 2024 | -$2.19 | -3750% |
NEOG is still losing money, but far less than before: $0.26 per share over the past year, against $5.03 at its worst in mid-2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NEOG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NEOG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.8M | +6.5% |
| Q2 2026 | $225.3M | -0.1% |
| Q1 2026 | $211.2M | -4.4% |
| Q4 2025 | $224.7M | -2.8% |
| Q3 2025 | $209.2M | -3.6% |
| Q2 2025 | $225.5M | -4.8% |
| Q1 2025 | $221M | -3.4% |
| Q4 2024 | $231.3M | +0.7% |
NEOG's revenue grew through 2023 and has held roughly level since: $223M last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +6.9 points |
| Q2 2026 | 1.4% | +273 points |
| Q1 2026 | -1.6% | -4 points |
| Q4 2025 | -2.4% | +195 points |
| Q3 2025 | -7.7% | -8.7 points |
| Q2 2025 | -271% | -277 points |
| Q1 2025 | 2.5% | -2.8 points |
| Q4 2024 | -198% | -204 points |
NEOG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NEOG on cash flow, with more consistent year-over-year improvement.
NEOG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | +$17.8M |
| Q2 2026 | $26.2M | +6353% |
| Q1 2026 | $11.1M | +$24.6M |
| Q4 2025 | $7.8M | -66% |
| Q3 2025 | -$13.1M | +$43.2M |
| Q2 2025 | $406K | -84% |
| Q1 2025 | -$13.5M | +$48.8M |
| Q4 2024 | $23.1M | +$31.8M |
NEOG's free cash flow has turned positive after four years mostly in the red: $50M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NEOG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NEOG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +600K shares |
| 1 year | +0.4% | +765K shares |
| 3 years | +0.6% | +1.3M shares |
| 5 years | +102% | +110M shares |
| Available history | +106% | +112M shares |
NEOG has 218M diluted shares, about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NEOG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 12.7x | High |
| Q2 2026 | 6.4x | High |
| Q3 2024 | 4.8x | High |
| Q2 2024 | 4.1x | High |
| Q1 2024 | 3.9x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q3 2023 | 4.4x | High |
| Q2 2023 | 5.7x | High |
NEOG's net debt is about 13 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NEOG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 25.0 | Neutral |
NEOG's weekly RSI is 51 (neutral) and its Stochastic is 25 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NEOG PE vs Healthcare Sector
| Metric | NEOG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEOG has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NEOG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 7.3% below |
| 20 week MA | $11.5 | 2.9% below |
| 50 week MA | $10.1 | 11% above |
| 100 week MA | $8.62 | 30% above |
| 200 week MA | $12.9 | 13% below |
NEOG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NEOG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.5 | $40.5 | +24% |
| 2021 | $40.5 | $44.4 | +9.7% |
| 2022 | $44.4 | $14.9 | -67% |
| 2023 | $14.9 | $20.1 | +35% |
| 2024 | $20.1 | $12.4 | -38% |
| 2025 | $12.4 | $7.13 | -43% |
| 2026 YTD | $7.13 | $11.2 | +57% |
NEOG has the edge over HIMS on returns for 2026, with the stronger performance.